Occurrence of inflammatory bowel disease during treatment of juvenile idiopathic arthritis with etanercept: a French retrospective study
Authors:
- Danièle CanioniDCDanièle Canioni
- Frank RuemmeleFRFrank Ruemmele
- Agnès DuquesneADAgnès Duquesne
- Jean-Yves ScoazecJSJean-Yves Scoazec
- Raymonde BouvierRBRaymonde Bouvier
- François ParafFPFrançois Paraf
- Jeanne LanguepinJLJeanne Languepin
- Carine H. WoutersCWCarine H. Wouters
- Marcel GuillotMGMarcel Guillot
- Pierre QuartierPQPierre Quartier
- Brigitte Bader-MeunierBBBrigitte Bader-Meunier
Open Access
- 14 May 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 49 (9) , 1694-1698
Abstract
Objectives. To identify juvenile idiopathic arthritis (JIA) patients who developed IBD during treatment with anti-TNF-α agents and better characterize the IBD clinical and pathological presentation. Methods. A retrospective French multicentre study included patients with a diagnosis of JIA according to the ILAR criteria who developed IBD while under anti-TNF-α therapy before 18 years of age. Intestinal biopsies were collected and reviewed by the same pathologist. Results. Eight patients were included. They had been treated with etanercept from 11 to 78 months before IBD onset. Gastro-intestinal symptoms included abdominal pain (six patients), diarrhoea (four patients), anorexia (four patients), anal abscess (three patients) and oral ulcers (one patient). Five patients presented with Crohn’s disease (CD) and three with indeterminate IBD, of whom four had severe pancolitis. Clinical remission of IBD was obtained in all patients after discontinuation of etanercept and initiation of IBD-specific therapy, including infliximab in six patients. Conclusion. IBD must be suspected in JIA patients treated with etanercept who develop intestinal symptoms, including anal abscess. This series raises the possibility of a relationship between etanercept therapy and the occurrence of IBD in a subset of patients with JIA.Keywords
This publication has 15 references indexed in Scilit:
- Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective studyRheumatology, 2009
- Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA RegistryAnnals of the Rheumatic Diseases, 2009
- Focus on adverse events of tumour necrosis factor α blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patientsAnnals of the Rheumatic Diseases, 2008
- Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritisArthritis & Rheumatism, 2008
- Autoimmune Diseases Induced by TNF-Targeted TherapiesMedicine, 2007
- Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti–tumor necrosis factor α agentsArthritis Care & Research, 2007
- Tumor Necrosis Factor-α Inhibitor Associated Ulcerative ColitisThe American Journal of the Medical Sciences, 2007
- Incidence, Clinical Presentation and Location at Diagnosis of Pediatric Inflammatory Bowel Disease: A Prospective Population‐Based Study in Northern France (1988‐1999)Journal of Pediatric Gastroenterology and Nutrition, 2005
- Development of Crohn Disease During Anti–TNF-α Therapy in a Child With Juvenile Idiopathic ArthritisJournal of Pediatric Gastroenterology and Nutrition, 2004
- Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset typeArthritis & Rheumatism, 2003